Latest Information Update: 10 Dec 2007
At a glance
- Originator FeRx
- Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
- Mechanism of Action Somatotropin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Neuroendocrine tumours
Most Recent Events
- 13 Jul 2004 Preclinical trials in Neuroendocrine tumours in USA (unspecified route)